This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
Est. Enrollment: 18 participants
Study Start Date: Aug 31, 2021
Study Completion Date: Sep 01, 2025
Age: 18 to 70 years